Vexas: towards molecular and phenotypic characterization

New work unveiled at EULAR 2024

2024-06-12

(Press-News.org) VEXAS is characterised by predominantly rheumatic and haematologic systemic involvement, and caused by somatic mutation in UBA1 – a gene encoding ubiquitin-activating enzyme 1,1,2 which is necessary for a post-translation modification that affects protein functions ranging from degradation to subcellular localisation and kinase activation.3 The syndrome was first described in 2020, but diagnosis can be challenging as the symptoms overlap with many other inflammatory conditions.1 Hot on the heels of this recent discovery, research is underway to better understand pathogenesis, clinical features, and potential treatment options.1

To support this, 6 patients were recruited from the IRCCS San Raffaele Hospital in Milan, Italy. The variant allele frequency of UBA1 mutant cells was quantified, and multiparametric immunophenotypic analysis and single cell RNA sequencing were performed on peripheral blood and bone marrow, focusing on hematopoietic stem/progenitor cells (HSPC). The results were compared to those from healthy age- and sex-matched controls. Additionally, to introduce UBA1 mutations and develop VEXAS models in healthy human HSPC, the group used cutting-edge gene-editing technologies.

Targeted sequencing supported a myeloid skewing of mutant HSPC in VEXAS patients, and multiparametric immunophenotypic analyses showed unbalanced HSPC composition in bone marrow, with 2- to 3-fold reduction of primitive stem cells, multipotent, and lymphoid progenitors – and 2-fold increase in myeloid progenitors – compared to matched healthy individuals. HSPC, myeloid-biased HSPC, and immature myeloid cells were increased by 3- to 4-fold in the circulation. Gene expression analysis of circulating monocytes displayed upregulation of inflammatory pathways and metabolic rewiring. Further metabolomic analyses confirmed hyperactivation of the glycolytic pathway and specific lipid metabolism.

The results from the single-cell RNA sequencing of bone marrow mononuclear cells identified a subpopulation of CD34+ cells specific to VEXAS patients – and revealed upregulated stress response and immune activation pathways across VEXAS cell clusters as compared to healthy controls.

In the VEXAS models, transplantation of gene-edited HSPC in immunodeficient mice resulted in a 100-fold reduction in circulating B cells, while NK and myeloid compartments were preserved.

The group conclude that mutations in UBA1 drive expansion of HSPC and enhance myelopoiesis-guided accumulation of myeloid precursors. The success of the new gene-editing models hold promise, and could be used in preclinical testing and validation of novel therapeutics for this rare disease.

Source

Campochiaro C, et al. Unraveling pathophysiology and hematopoiesis of VEXAS syndrome by multi-omics analysis and targeted gene editing. Presented at EULAR 2024; OP0073.

Ann Rheum Dis 2024; DOI: 10.1136/annrheumdis-2024-eular.3532.

References

1. Kobak S. VEXAS syndrome: Current clinical, diagnostic and treatment approaches. Intractable Rare Dis Res 2023;12(3):170–9.

2. Poulter JA, et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 2021;137:3676–81.

3. Guo HJ, et al. Biochemistry, Ubiquitination. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK556052/

About EULAR

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

Contact

EULAR Communications, communications@eular.org

Notes to Editors

EULAR Recommendations

EULAR School of Rheumatology

EULAR Press Releases

END

ELSE PRESS RELEASES FROM THIS DATE:

Location, location, location – does it matter in psoriatic arthritis?

2024-06-12

Arthritis affects various joints differently, despite systemic inflammatory cues.2 In people with rheumatoid arthritis, transcriptomic variances identified in synovial fibroblasts from various joint sites have been shown to translate into joint-specific phenotypes with distinct characteristics and responsiveness to cytokines.2,3 These findings suggest that different joints may potentially respond variably to specific immunosuppressive treatments. To expand on this, Ciurea and colleagues set out to investigate whether joints at different anatomical locations in people with PsA might respond differently to treatment with a tumour necrosis ...

Stopping the march

2024-06-12

The estimated prevalence of psoriatic arthritis (PsA) in people with psoriasis ranges widely –between 6% and 42% – but in most cases, skin symptoms precede PsA, thus making skin psoriasis a model for pre-PsA.2 Assuming that there are shared pathways in the pathogenesis, it is possible that stringent treatment of moderate-to-severe psoriasis could reduce progression to clinically overt PsA.3,4 Biologic treatments are effective at controlling psoriasis, but there are no conclusive data that these treatments help prevent people from developing PsA. Several risk factors for transition have previously been identified by a EULAR taskforce.5 ...

Predicting response in treatment-naïve RA

2024-06-12

The synovial tissue inflammation seen in RA shows high degree of heterogeneity – which may be a factor in people’s variable response to treatments. We also know that distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis.1 The potential of high-throughput analyses has been shown, and these technologies can help dissect disease heterogeneity and identify novel biomarkers that could be used in prognosis.2 To explore this further, 373 treatment-naïve RA patients were enrolled and given an ultrasound-guided synovial tissue biopsy. The synovitis degree and synovial pathotype was then determined for ...

Testing the systemic score for Still’s disease

2024-06-12

A multi-centre, observational, prospective study was designed to evaluate the clinical usefulness of the systemic score in predicting life-threatening evolution – defined as the development of macrophage activation syndrome (MAS) and/or mortality. The intention was also to derive a more aggressive clinical patient subset. To achieve this, Ruscitti and colleagues collected data from 597 patients taking part in the GIRRCS (Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale) AOSD-study ...

Early RA: Disease trajectories and pain

2024-06-12

The 2024 EULAR congress in Vienna included a clinical abstract session focusing on pain and prognosis in RA, where two groups presented their research into ways to characterise early RA. The first looked at dissecting early RA patient trajectories through time-independent disease state patterns of inflammation in blood or joints. Presenting the work, Nils Steinz said “Previous studies have identified smooth time trajectories of rapid, slow, or no progression of disease activity, assessed through DAS28. In real life, we observe more chaotic disease evolvements – and particularly the detours could ...

Testing the thresholds

2024-06-12

However, this recommendation is not always followed in practice. This could be because the ASDAS was developed for research, and it is not known how well it performs in daily practice. Possibly, the cut-off of 2.1 as currently endorsed may be too strict in an everyday setting. To address this, Webers and colleagues set out to investigate which ASDAS cut-off values correspond best with treatment intensification in practice. Data were taken from a prospective multi-centre registry for SpA, and treatment ...

Ingestible microbiome sampling pill technology advances

2024-06-12

Significant progress has been made at Tufts University School of Engineering in the development of a small device, about the size of a vitamin pill, that can be swallowed and passed through the gastrointestinal tract to sample the full inventory of microorganisms in an individual’s gastro-intestinal tract. This device has the potential to advance research on the relationship between resident bacteria and a wide range of health conditions. It could also serve as a diagnostic tool for adjusting the microbiome or administering drugs to treat those conditions. The device has completed ...

Just thinking about a location activates mental maps in the brain

2024-06-12

As you travel your usual route to work or the grocery store, your brain engages cognitive maps stored in your hippocampus and entorhinal cortex. These maps store information about paths you have taken and locations you have been to before, so you can navigate whenever you go there. New research from MIT has found that such mental maps also are created and activated when you merely think about sequences of experiences, in the absence of any physical movement or sensory input. In an animal study, the researchers found that the entorhinal cortex harbors a cognitive map of what animals experience while they use a joystick to browse through a sequence of images. ...

Obesity-cancer connection discovery suggests strategies for improving immunotherapy

2024-06-12

Immune system cells called macrophages play an unexpected role in the complicated connection between obesity and cancer, a Vanderbilt University Medical Center-led research team has discovered. Obesity increases the frequency of macrophages in tumors and induces their expression of the immune checkpoint protein PD-1 — a target of cancer immunotherapies. The findings, published June 12 in the journal Nature, provide a mechanistic explanation for how obesity can contribute to both increased cancer ...

Smartwatches offer window into Parkinson's disease progression

2024-06-12

Ubiquitous wearable technologies, like smartwatches, could help researchers better understand progressive neurological disorders like Parkinson’s disease and speed up the approval of new therapies, a critical need given that no drugs exist to slow progression of the world’s fastest growing brain disease. New research appearing today in the journal njp Parkinson’s Disease adds to growing evidence that widely used and user-friendly consumer devices, in this instance an Apple Watch paired with an iPhone, ...

Vexas: towards molecular and phenotypic characterization

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: